Profile data is unavailable for this security.
About the company
Shattuck Labs, Inc. is a clinical-stage biotechnology company. The Company is engaged in the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease. Its lead product candidate, SL-172154, is designed to simultaneously inhibit the CD47/SIRPa macrophage checkpoint interaction and activate the CD40 costimulatory receptor to induce an antitumor immune response. It is conducting a Phase IA/B clinical trial in patients with acute myeloid leukemia (AML) and HR-MDS. It has completed the Phase IA dose-escalation portion of this clinical trial and are enrolling patients in the Phase IB expansion cohorts evaluating SL-172154 in combination with azacitidine in frontline HR-MDS or frontline TP53 mutant (TP53m) AML. It has developed the ARC platform to address the need for a single therapeutic that consolidates multiple immune functions.
- Revenue in USD (TTM)4.12m
- Net income in USD-85.28m
- Incorporated2016
- Employees75.00
- LocationShattuck Labs Inc500 W. 5Th Street, Suite 100AUSTIN 78701United StatesUSA
- Phone+1 (512) 900-4690
- Websitehttps://www.shattucklabs.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Protara Therapeutics Inc | 0.00 | -40.69m | 52.40m | 26.00 | -- | 0.5693 | -- | -- | -3.19 | -3.19 | 0.00 | 4.46 | 0.00 | -- | -- | 0.00 | -41.35 | -37.02 | -43.70 | -38.29 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 38.71 | -- | -17.67 | -- |
| Angion Biomedica Corp | 0.00 | -38.66m | 54.73m | 32.00 | -- | -- | -- | -- | -4.83 | -4.83 | 0.00 | -0.161 | 0.00 | -- | -- | 0.00 | -144.89 | -105.91 | -202.49 | -331.69 | -- | -- | -- | -712.81 | -- | -- | -- | -- | -100.00 | -- | 9.31 | -- | -- | -- |
| Unicycive Therapeutics Inc | 0.00 | -24.41m | 55.67m | 14.00 | -- | -- | -- | -- | -0.2843 | -0.2843 | 0.00 | 0.7193 | 0.00 | -- | -- | 0.00 | -68.77 | -218.20 | -118.93 | -609.54 | -- | -- | -- | -3,877.49 | -- | -- | 0.00 | -- | -29.02 | -- | -73.95 | -- | -- | -- |
| Prenetics Global Ltd | 22.50m | -45.63m | 56.20m | 320.00 | -- | 0.2599 | -- | 2.50 | -3.79 | -4.14 | 1.86 | 17.70 | 0.0875 | 3.23 | 4.63 | 70,304.00 | -18.52 | -- | -22.89 | -- | 52.31 | -- | -211.67 | -- | 1.98 | -8.67 | 0.0122 | -- | 65.17 | -- | 75.91 | -- | -- | -- |
| Shattuck Labs Inc | 4.12m | -85.28m | 56.32m | 75.00 | -- | 0.5091 | -- | 13.66 | -1.85 | -1.85 | 0.0883 | 2.32 | 0.029 | -- | -- | 54,986.67 | -60.08 | -29.14 | -66.66 | -32.42 | -- | -- | -2,067.99 | -565.33 | -- | -- | 0.00 | -- | 154.14 | -40.62 | 14.37 | -- | -19.15 | -- |
| Immuneering Corp | 0.00 | -56.07m | 56.34m | 66.00 | -- | 0.8497 | -- | -- | -1.91 | -1.91 | 0.00 | 2.24 | 0.00 | -- | -- | 0.00 | -55.52 | -- | -59.10 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -100.00 | -- | -5.86 | -- | -- | -- |
| Gain Therapeutics Inc | 0.00 | -21.60m | 56.56m | 29.00 | -- | 4.73 | -- | -- | -1.33 | -1.33 | 0.00 | 0.4682 | 0.00 | -- | -- | 0.00 | -115.33 | -- | -170.44 | -- | -- | -- | -- | -13,827.07 | -- | -- | 0.0396 | -- | -60.62 | 21.77 | -26.59 | -- | 13.96 | -- |
| OS Therapies Inc | 0.00 | -6.55m | 57.14m | 4.00 | -- | -- | -- | -- | -0.3011 | -0.3011 | 0.00 | -1.32 | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -0.9763 | -- | -- | -- | -- | -24.09 | -- | -- | -- |
| Actinium Pharmaceuticals Inc | 81.00k | -42.62m | 59.90m | 49.00 | -- | 1.34 | -- | 739.46 | -1.52 | -1.52 | 0.0029 | 1.43 | 0.0009 | -- | -- | 1,653.06 | -45.12 | -46.98 | -50.13 | -52.71 | -- | -- | -52,620.99 | -6,683.95 | -- | -- | 0.0006 | -- | -92.14 | -- | -47.86 | -- | 9.75 | -- |
| Mural Oncology PLC | 0.00 | -173.30m | 59.97m | 117.00 | -- | 0.2913 | -- | -- | -10.35 | -10.35 | 0.00 | 12.09 | 0.00 | -- | -- | 0.00 | -131.01 | -- | -164.28 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -9.29 | -- | -- | -- |
| Enzo Biochem Inc | 31.91m | -9.82m | 60.08m | 125.00 | -- | 1.07 | -- | 1.88 | -0.194 | -0.5102 | 0.6268 | 1.07 | 0.3073 | 2.34 | 7.25 | 255,256.00 | -9.46 | -14.58 | -13.74 | -19.56 | 45.86 | 40.43 | -30.77 | -26.20 | 2.55 | -- | 0.0047 | -- | 2.72 | -17.03 | 60.77 | -- | -41.75 | -- |
| Omega Therapeutics Inc | 6.31m | -78.90m | 60.12m | 93.00 | -- | 2.29 | -- | 9.52 | -1.43 | -1.43 | 0.1145 | 0.4762 | 0.0318 | -- | 6.67 | 67,892.48 | -39.72 | -- | -46.68 | -- | -- | -- | -1,249.54 | -- | -- | -- | 0.3917 | -- | 49.25 | -- | 5.13 | -- | -- | -- |
| Bioqual Inc | -100.00bn | -100.00bn | 60.37m | 108.00 | -- | 1.63 | -- | -- | -- | -- | -- | 41.34 | -- | -- | -- | -- | -- | 8.14 | -- | 9.52 | -- | 19.36 | -- | 7.13 | -- | -- | 0.00 | 21.43 | -5.27 | 11.79 | -84.12 | -25.26 | 1.60 | 10.76 |
| Precision BioSciences Inc | 75.10m | 11.48m | 60.62m | 108.00 | 10.97 | 0.9664 | 3.86 | 0.8072 | 0.7641 | 0.0524 | 12.85 | 8.67 | 0.4729 | -- | 29.70 | 688,954.10 | 7.23 | -35.35 | 9.00 | -44.22 | -- | -- | 15.28 | -147.50 | -- | -- | 0.2557 | -- | 94.15 | 34.96 | 41.67 | -- | -32.01 | -- |
Data as of Nov 08 2024. Currency figures normalised to Shattuck Labs Inc's reporting currency: US Dollar USD
63.26%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Fidelity Management & Research Co. LLCas of 30 Jun 2024 | 7.13m | 14.94% |
| Redmile Group LLCas of 30 Jun 2024 | 5.62m | 11.77% |
| Prosight Management LPas of 14 Aug 2024 | 5.37m | 11.25% |
| Adage Capital Management LPas of 30 Jun 2024 | 2.75m | 5.75% |
| The Vanguard Group, Inc.as of 30 Sep 2024 | 2.40m | 5.03% |
| BlackRock Fund Advisorsas of 30 Jun 2024 | 2.27m | 4.75% |
| Franklin Advisers, Inc.as of 30 Jun 2024 | 1.57m | 3.29% |
| The Clark Estates, Inc.as of 30 Jun 2024 | 1.48m | 3.09% |
| Geode Capital Management LLCas of 30 Jun 2024 | 904.07k | 1.89% |
| SSgA Funds Management, Inc.as of 30 Jun 2024 | 710.83k | 1.49% |
More ▼
Data from 30 Jun 2024 - 30 Jun 2024Source: FactSet Research Systems Inc.
